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Abstract
Background: Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal,
available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed.
Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India.
Methods: This was a 3-arm multicentre, open-label, randomized, controlled clinical trial to compare three treatment
regimens for VL in East Africa: paromomycin sulphate (PM) at 15 mg/kg/day for 21 days versus sodium stibogluconate (SSG)
at 20 mg/kg/day for 30 days; and the combination of both dose regimens for 17 days. The primary efficacy endpoint was
cure based on parasite-free tissue aspirates taken 6 months after treatment.
Findings: Overall, 135 patients per arm were enrolled at five centres in Sudan (2 sites), Kenya (1) and Ethiopia (2), when the
PM arm had to be discontinued due to poor efficacy. The trial has continued with the higher dose of PM as well as the
combination of PM and SSG arms. These results will be reported later. Baseline patient characteristics were similar among
treatment arms. The overall cure with PM was significantly inferior to that with SSG (63.8% versus 92.2%; difference 28.5%,
95%CI 18.8% to 38.8%, p,0.001). The efficacy of PM varied among centres and was significantly lower in Sudan (14.3% and
46.7%) than in Kenya (80.0%) and Ethiopia (75.0% and 96.6%). No major safety issues with PM were identified.
Conclusion: The efficacy of PM at 15 mg/kg/day for 21 days was inadequate, particularly in Sudan. The efficacy of higher
doses and the combination treatment warrant further studies.
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Introduction
Visceral leishmaniasis (VL) is among the most neglected and
serious tropical diseases [1,2]. The disease is caused by protozoal
parasites of the genus Leishmania transmitted to humans by bites of
female sandflies. The incubation period varies from 2 to 6 months.
The most prominent clinical symptoms are recurring fever,
hepatosplenomegaly, lymphadenopathy, anemia, weight loss,
and weakness. Not all those infected develop symptoms, but
factors such as malnutrition and immune suppression including
HIV coinfection increase the likelihood that the infection will
manifest clinically. VL is usually fatal if not treated.
The WHO estimates that worldwide about 500,000 new cases
of VL occur every year. 90% of cases occur in five countries: India
(especially Bihar State), Bangladesh, Nepal, Sudan and north
eastern Brazil [3]. In East Africa, the annual number of cases of
www.plosntds.org 1 October 2010 | Volume 4 | Issue 10 | e709VL is estimated at 30,000 [2] and related deaths at 4000 [4].
Especially in Sudan, Ethiopia and Kenya, VL is associated with
high mortality and morbidity, exacerbated by poor nutritional
status and the remote location of VL endemic areas.
For decades, antimony-based treatments, such as sodium
stibogluconate (SSG), have been the mainstay of treatment,
enshrined in the national treatment guidelines of Sudan, Ethiopia,
and Kenya. However, the drug has unpredictable toxicity [5,6]
and the requisite 4-week hospitalization imposes a huge economic
burden on poor families [7]. In addition, high treatment failure to
SSG has been identified in some endemic areas with an incidence
of up to 60% in some regions of Bihar, India [8]. However, no
resistance to SSG has been documented in Africa. SSG has also
been shown to be less effective and more toxic in HIV-infected
patients [9]. Other drugs available for VL include paramomycin,
miltefosine and AmBisome. However, none of these drugs is
widely available or registered in Africa, and all have limitations
due to cost, treatment duration, toxicity or heat stability.
Therefore, new and better treatment options are urgently needed
to replace or complement the few currently available drugs.
Paromomycin (PM), also known as aminosidine, is a broad-
spectrum aminoglycoside antibiotic [10], of which an injectable
sulphate formulation has been marketed for the treatment of
bacterial and parasitic infections in several countries for over 35
years. In the 1990s, PM was shown to be efficacious against VL in
pilot and phase II studies in India [11–13], Kenya [14] and Sudan
[15,16], both as monotherapy and in combination with SSG. In
Sudan, use of PM has been in combination, so its efficacy in
monotherapy had not been established before this trial. Recently,
in a large randomized, controlled phase III trial enrolling 667
patients with acute symptomatic VL in India, definitive cure rates
with PM were comparable to those with amphotericin B, and its
safety profile was excellent [17]. Therefore, the aim of this trial
was to assess the efficacy and safety of PM alone and in
combination with SSG in comparison to the standard reference
treatment for VL in East Africa. However, because the 15 mg/kg/
day PM arm was prematurely discontinued due to poor efficacy,
only the safety and efficacy findings of PM at this dose in
comparison to SSG are given here. For the combination
treatment, the study has continued at a higher dose of PM,
20 mg/kg/day, and results will be published as complete data
become available.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design and patients
This prospective, randomized, open-label, three-arm trial was
carried out at five centres in three countries of East Africa: MSF
Holland treatment centre, Um el Kher, Gedaref State, Sudan;
Ministry of Health Hospital, Kassab, Gedaref State, Sudan;
Leishmania Research and Treatment Centre, Gondar University
Hospital, Amhara Regional State, northern Ethiopia; Leishmania
Research and Treatment Centre, Arba Minch Hospital, Gama
Gofa, Southern Nations, Nationalities and Peoples (SNNP)
Regional State, southern Ethiopia; and Centre for Clinical
Research (CCR), Kenya Medical Research Institute (KEMRI),
Nairobi, Kenya.
Eligible patients were 4–60 years old and had to have clinical
symptoms (fever and splenomegaly) and a diagnosis of VL,
confirmed by microscopic verification of parasites in spleen, lymph
node or bone marrow tissue aspirates. Patients were excluded if
they: (1) had taken any antileishmanial drug in the preceding 6
months; (2) showed severe protein or caloric malnutrition
(Kwashiokor or marasmus); (3) had previous hypersensitivity
reaction to SSG or aminoglycosides; (4) had a concomitant severe
infection (except HIV) or any other serious underlying (cardiac,
renal, hepatic) disease; (5) had conditions associated with
splenomegaly, such as schistosomiasis; (6) had a history of cardiac
arrhythmia or an abnormal electrocardiogram (ECG); (7) were
pregnant or lactating; (8) had any relevant outliers of safety
laboratory parameters (hemoglobin ,5 g/dL, white blood cells
,1610
3/mm
3, platelets ,40,000/mm
3, liver function test values
.3 times higher than upper limit of normal, serum creatinine
values above upper limit of normal); or (9) had clinical hearing
loss.
Eligible patients were identified during regular field trips to
villages in the endemic areas, or presented spontaneously at the
hospital trial sites. At presentation, the trial and its purpose were
described to patients in their local language. If patients agreed,
they were transported to the trial sites for further investigation of
eligibility. If eligible, patients were enrolled after written informed
consent was signed either by themselves or, in case of minors, by
their parent(s) or guardian. The study protocol was approved in
each country by the relevant Institutional National Scientific
Ethics Committees and the Ethics Committee of the London
School of Hygiene and Tropical Medicine. The trial was
registered with ClinicalTrials.gov (number NCT00255567).
Ethics Statement
The trial was conducted in accordance with the Declaration of
Helsinki (2002 version) relating to the conduct of research on
human subjects and followed the International Committee on
Harmonisation (ICH) guidelines for the conduct of clinical trials.
All trial site personnel received relevant training in Good Clinical
Practice (GCP). The WHO-TDR handbooks were used for
training and for reference before and during the trial.
A Data Safety Monitoring Board (DSMB) was appointed at trial
start and met regularly throughout the trial. Members were drawn
Author Summary
Visceral leishmaniasis (VL) is a fatal parasitic disease with
500,000 new cases each year according to WHO estimates.
New and better treatment options are urgently needed in
disease endemic areas due to the long courses, toxicity
and development of resistance to current treatments.
Recently, the antibiotic paromomycin was tested and
registered in India to treat this disease. The current study
describes a clinical trial to test the effectiveness of
injectable paromomycin, either alone or in combination
with the standard drug sodium stibogluconate in three
East African countries—Sudan, Kenya and Ethiopia. The
study showed that at the same paromomycin dose that
was successfully used and registered in India, a far poorer
outcome was obtained, particularly in Sudan, suggesting
that there are either differences in the patients ability to
respond to the drug or in the susceptibility of parasites in
East Africa compared with those in India. However, no
major safety concerns were noted with the treatment.
Further research was initiated to see if a higher dose of
paromomycin would perform better, especially in Sudan.
The results of this and the performance of the combination
arm will be reported later. Our study highlights the
importance of considering geographical differences to
treatment responses.
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monitored at all sites by GCP-trained monitors recruited from
Sudan, Ethiopia, Kenya and Uganda. Monitors were allocated to
trial sites not within their own country to ensure independence
from investigators and to ease communications when dealing with
issues arising at the trial sites. Wherever possible during
monitoring visits, data entered into the trial case report forms
(CRFs) were checked against source data (e.g. laboratory log
books, analyzer printouts, nursing records) for verification.
Randomization
Allocation to treatment was by means of sequentially numbered,
sealed envelopes, generated from a computerized randomization
list. Each centre received a box of uniquely numbered sealed
envelopes from the LEAP Trial Coordination Centre in Nairobi,
where centralized randomization and envelope preparation were
carried out in blocks of 15 to maintain randomization balance
within centers. For each enrolled patient, the investigator took the
next lowest numbered envelope and allocated the patient to the
treatment given on the card inside.
Treatment
Patients received either PM alone (manufactured by Gland
Pharma, India) at a daily dose of 15 mg/kg body weight given
intramuscularly for 21 days, or SSG alone (manufactured by
Albert David, India) at a daily dose of 20 mg/kg body weight
given intramuscularly or intravenously (KEMRI trial site) for 30
days, or the combination of both at the same daily doses for 17
days. For the duration of treatment, patients were treated as
inpatients, thus ensuring high compliance. Patients were followed
up at 3 (optional) and 6 months after treatment. If patients did not
attend follow-up, health workers visited the patient’s village to try
to establish if he/she was alive and well, had died or had moved
away. Patients for whom trial medication had to be stopped due to
lack of response or a serious adverse event (SAE) were given rescue
medication (liposomal amphotericin B, manufactured as Ambi-
someH by Gilead, USA) according to national VL guidelines from
participating countries.
Baseline, efficacy and safety measurements
Baseline information was obtained from all patients through a
standard clinical assessment. Patients were offered counseling and
testing for HIV in accordance to national guidelines, though this
was not a prerequisite to inclusion. Formal assessments were
carried out at baseline, days 7, 14, 21, end of treatment, and 3 and
6 months after treatment. This included a clinical assessment
(clinical symptoms, vital signs, weight, height, spleen and liver
size), hemoglobin, white cell count (not performed in Um el Kher
site), platelets, urea, creatinine, liver function tests (bilirubin,
aspartate aminotransferase, alanine aminotransferase, alkaline
phosphatase), urinalysis, ECG and audiometry (not performed in
Um le Kher site). Amylase test was not routinely done in all sites
but was performed by investigators if clinically indicated. ECG
printouts with corrected QT intervals were interpreted by the site
physician and were stored with source documents. Audiometry
was performed using a standardized procedure by site investigators
who were trained by a qualified audiometrist and recorded as
hearing levels in dB at 0.25, 0.5, 1, 2, 4 and 8 kHz frequencies
[18]. All reported abnormal audiometric readings were reviewed
by the audiometrist. Abnormal audiometry was defined as any
patient with audiometric readings in either of the following
categories: mild 26–40 dBHL (decibel hearing level); moderate
41–55 dBHL; moderately severe 56–70 dBHL; severe 71–90
dBHL; or profound .90 dBHL. Clinically significant hearing loss
or clinically abnormal hearing was defined as any patient who
reports to have a hearing loss.
Parasitology was done at baseline, end of treatment and 6
months after treatment. A spleen, lymph node or bone marrow
aspirate was performed at diagnosis and for assessment of cure.
This varied between sites according to local guidelines. During
follow-up, bone marrow aspirates were done in the event of spleen
or lymph node regression.
Outcome measures
The primary endpoint was cure (ie, efficacy) at 6 months after
treatment, based on the absence of leishmania parasites in tissue
aspirates. Any patient who died from VL, received rescue
medication during the treatment period or had parasites visualized
on microscopy at the 6-month assessment was regarded as a
treatment failure in primary efficacy analyses.
The secondary endpoint was initial cure at the end of treatment
(i.e. at day 22 for PM, at day 31 for SSG, and at day 18 for the
combination). Any patient who died from VL, received rescue
medication during the period of the trial or had parasites
visualized on microscopy at the end of treatment was regarded
as a treatment failure in the secondary efficacy analyses. Clinical
and biological parameters such as temperature, weight, spleen size
and hemoglobin were used by clinicians to decide if rescue
medication was indicated.
A slow responder was defined as a patient who was parasite
positive at end of treatment but was deemed not to require rescue
medication due to improvements in clinical and biological
parameters and who went on to clear parasites at the primary
endpoint (6-month assessment). Therefore, a treatment failure at
initial cure could be a treatment success at 6-month follow-up as a
slow responder to treatment, provided that no rescue medication
was administered.
The evaluation of safety was based on adverse event (AE)
monitoring, ECGs, safety laboratory analyses (hematology and
biochemistry) and audiometry. AEs were classified according to
MedDRA, version 10, and defined as treatment emergent (TEAE)
if onset was between the first day of treatment and 30 days after
treatment.
Statistical analysis
Data were analyzed with Stata software, version 9. At baseline,
continuous data were summarized using mean and standard
deviation (SD) and binary data using proportions. Primary and
secondary efficacy analyses were by intention to treat (ITT).
Where missing parasitological data at the primary endpoint (6-
month follow-up) occurred due to loss to follow-up or death
unrelated to VL in patients not receiving rescue medication before
loss, two analysis approaches were taken within the ITT
framework: complete-case analysis, where patients with missing
data were excluded, and worst-case analysis, where the missing
outcome was assumed to be treatment failure.
The number and percentage cured is presented by arm and
centre. Fisher’s exact test was used to assess evidence of significant
differences in cure.
TEAE rate per arm was calculated as the number of events per
arm divided by the person-time at risk. For the rate analysis,
patient-time at risk was calculated as the number of patients per
arm multiplied by the maximum patient-time at risk for TEAE
(treatment period plus 30 days, i.e. 60 days for SSG and 51 days
for PM). Poisson regression was used to obtain a rate ratio
comparing PM to SSG, adjusted for centre.
At the start of the trial, it was estimated that 217 patients would
be required per arm to detect a 10% difference in efficacy among
Clinical Trial of Paromomycin in East Africa
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95% efficacy in the reference (SSG) arm, and a 20% drop-out rate
from the analysis (10% due to HIV co-infection and 10% due to
loss to follow-up between end of treatment and 6-month
assessment). HIV infection was not an exclusion criterion. Whilst
co-infection was expected to be low, efficacy and toxicity may vary
in those with and without HIV. A comparison of PM to SSG is
presented here following recruitment of 135 patients per arm after
which point recruitment into the 15 mg/kg/day PM arm was
stopped.
Figure 1. Patient flow chart. *Excluded from the efficacy analysis: 24 patients were lost to follow-up, and three died (n=2 deaths unrelated to VL
and n=1 death related to VL). Patients who were given rescue medication or who had died from VL were considered treatment failures; i.e. efficacy
complete-case analysis set for SSG, n=116 and for PM, n=127.
doi:10.1371/journal.pntd.0000709.g001
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Of 926 patients screened for eligibility, 405 were randomly
allocated to one of the three treatment arms (135 per arm). Of
these, 135 patients were recruited in Gondar, 90 each in Arba
Minch and Um el Kher and 45 each in Kassab and Kenya
(Figure 1). The first patient was recruited in November 2004, and
the last follow-up was done in April 2008.
Baseline characteristics
Demographic and clinical characteristics were similar across
treatment arms (Table 1). About 50% of patients were children,
and the ratio of males to females in both the SSG and PM arms
was about 3:1. Common disease symptoms were fever, weight loss,
fatigue, headache and loss of appetite, each affecting more than
two thirds of patients across treatment arms (Table 1). Mean
hemoglobin concentration was about 8.0 g/dL. Neither baseline
laboratory parameters nor vital signs or parasite counts showed
significant differences between treatment arms (data not shown).
In all arms, most patients had significant splenomegaly and were
malnourished, whereas the rate of HIV co-infection was low (3.7%
overall) (Table 1). A third of all patients in each arm did not
undergo HIV testing; however, of those tested, they were mainly
concentrated in Gondar, northern Ethiopia: seven (7.8%) in
Gondar, two (3.3%) in Arba Minch and one (1.1%) in Um el
Kher.
Efficacy
In the SSG arm (30-day treatment period), two patients received
only 14 days of SSG treatment; in the PM arm (21-day treatment
period), one patient received 20 days of PM treatment and 1 day
of SSG on day 2. In efficacy analyses, these patients were assumed
to have received allocated treatment in full, as per ITT.
In the SSG arm, 17 patients were lost between end of treatment
and 6 months, and there was one death unrelated to VL during
follow-up leading to a denominator of 116 in the complete-case
analysis. In the PM arm, seven patients were lost, and there was
one unrelated death leading to a complete-case denominator of
127.
At 6 months after treatment, the complete-case analysis shows
that the primary cure with PM was significantly inferior to that
with SSG standard treatment (63.8% versus 92.2%; difference
28.5%, 95%CI 18.8% to 38.8%, p,0.001). However, efficacy of
PM varied substantially across sites (p,0.001; Table 2). It was
poorest and significantly inferior to SSG at the Sudanese sites of
Um el Kher and Kassab. In Gondar (Ethiopia) and Kenya, the
efficacy of PM was between 75% and 80%, but there was less
evidence of a difference to SSG in Gondar (p=0.066) and none in
Kenya (p=0.224). In Arba Minch (Ethiopia), PM and SSG
Table 1. Baseline demographic and clinical characteristics.
SSG
n=135
PM
n=135
Age [years] 16.7 (10.4) 17.8 (11.1)
Children (4–14 years) 69 (51.1%) 67 (49.6%)
Adults ($15 years) 66 (48.9%) 68 (50.4%)
Sex Female 34 (25.2%) 31 (23.0%)
Male 101 (74.8%) 104 (77.0%)
Symptoms Fever 133 (98.5%) 133 (98.5%)
Weight loss 114 (84.4%) 111 (82.2%)
Fatigue 109 (80.7%) 102 (75.6%)
Headache 94 (69.6%) 98 (72.6%)
Loss of appetite 93 (68.9%) 91 (67.4%)
Cough 91 (67.4%) 83 (61.5%)
Abdominal pain 89 (65.9%) 88 (65.2%)
Night sweats 89 (65.9%) 85 (62.9%)
Abdominal swelling 77 (57.0%) 84 (62.2%)
Breathlessness 63 (46.7%) 59 (43.7%)
Epistaxis 46 (34.1%) 51 (37.8%)
Diarrhea 34 (25.2%) 31 (23.0%)
Swelling of legs 27 (20.0%) 20 (14.8%)
Organ size [cm] Spleen 8.2 (4.3) 8.3 (4.9)
Liver 2.9 (2.4) 2.9 (2.3)
Nutritional status* Severe underweight 17 (12.6%) 17 (12.6%)
Underweight 61 (45.2%) 67 (49.7%)
Normal weight 57 (42.2%) 50 (37.0%)
Overweight 0 (0%) 0 (0%)
Co-infections Malaria 7 (5.2%) 5 (3.7%)
Pneumonia 6 (4.4%) 4 (3.0%)
HIV-positive 4 (3.0%) 6 (4.4%)
HIV-negative 87 (64.4%) 86 (63.7%)
HIV-not tested 44 (32.6%) 43 (31.9%)
Data are n (%) or mean (SD). Differences between groups were not statistically
significant (all p.0.1).
*Children: Weight for age defined as severely underweight if ,60%,
underweight if between 60% and 80%, normal if .80%. Adults: BMI defined as
severely underweight if ,16, underweight if between 16.0 and 18.4, normal if
between 18.5 and 24.9.
doi:10.1371/journal.pntd.0000709.t001
Table 2. Cure (efficacy) at end of treatment and at 6 months
after treatment.
SSG PM P
*{
End of treatment
Overall 123/134 (91.8%) 91/135 (67.4%) ,0.001
N Um el Kher, Sudan 26/29 (89.7%) 10/30 (33.3%) ,0.001
N Kassab, Sudan 14/15 (93.3%) 9/15 (60.0%) 0.080
N Kenya 15/15 (100%) 13/15 (86.7%) 0.483
N Gondar, Ethiopia 40/45 (88.9%) 30/45 (66.7%) 0.021
N Arba Minch, Ethiopia 28/30 (93.3%) 29/30 (96.7%) 1.000
P*{ 0.832 ,0.001
6-months after treatment
Overall 107/116 (92.2%) 81/127 (63.8%)
1 ,0.001
N Um el Kher, Sudan 14/17 (82.4%) 4/28 (14.3%) ,0.001
N Kassab, Sudan 14/15 (93.3%) 7/15 (46.7%) 0.014
N Kenya 15/15 (100.0%) 12/15 (80.0%) 0.224
N Gondar, Ethiopia 37/40 (92.5%) 30/40 (75.0%) 0.066
N Arba Minch, Ethiopia 27/29 (93.1%) 28/29 (96.6%) 1.000
P*{ 0.568 ,0.001
1One patient without parasitology done at 6 months was considered as
treatment failure.
*p value from Fisher’s exact test.
{Comparison across arms within sites.
{Comparison across sites within arms.
doi:10.1371/journal.pntd.0000709.t002
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variation in the efficacy of SSG across centres (p=0.568).
A worst-case primary efficacy analysis also showed significantly
lower efficacy of PM than of SSG (60.0% versus 79.3%; difference
19.3%; 95%CI 8.5% to 30.0%, p,0.001). Effects seen were less
marked due to higher loss to follow-up in the SSG arm.
The findings for parasite clearance at the end of treatment
(Table 2) and the proportion of slow responders (i.e. patients still
having detectable parasites at the end of treatment, without any
rescue medication given) were similar in both arms. Poorer
efficacy of PM at the end of treatment was also reflected by a
significantly lower regression (ANOVA p=0.001, adjusting for
baseline measurements and centre) of spleen size (mean decrease
3.92 cm, 95%CI 4.49 to 3.35) compared with that of patients
treated with SSG (mean decrease 4.83 cm, 95%CI 5.38 to 4.28).
The subgroup of HIV-positive patients was small; however, in
the SSG arm three out of four patients (75%) were cured at 6
months, whereas in the PM arm only one out of six (17%) was
cured.
Safety
Treatment with both SSG and PM resulted in an increase of
liver enzymes, amylase and alkaline phosphatase, which abated
spontaneously whilst on treatment (data not shown). On average,
vital signs normalized during treatment, although slightly delayed
in the PM arm. Less than 1% of patients receiving either SSG or
PM developed ECG abnormalities and no clinically significant
abnormal audiometry readings were detected by the final
assessment.
Fewer patients in the PM arm than in the SSG arm were
affected by AEs (Table 3). However, after taking into account the
shorter treatment duration with PM than with SSG, there was
only weak evidence of a lower rate of TEAEs in the PM arm
(adjusted rate ratio 0.78, 95%CI 0.61 to 0.99, p=0.041). Increases
of liver enzymes and injection site pain were the most common
AEs in both groups, followed by infections and epistaxis (Table 4).
SAEs were reported in eight (5.9%) SSG patients and five
(3.7%) PM patients (Table 3). Two patients in each arm
prematurely stopped treatment due to SAEs and received rescue
medication, and overall five patients died (Figure 1). Two deaths
occurred during hospitalization, both due to renal failure in
patients receiving SSG, and three after discharge due to other
infections, one in the SSG and two in the PM arm. Among the
non-fatal SAEs that were considered unlikely, possibly or probably
related to study drug, there was one case of clinical pancreatitis
and one of seriously elevated serum amylase with SSG and single
cases of anemia, cardiac failure, and thrombocytopenia with PM.
There were no marked differences in reported SAE rates among
sites.
Discussion
Clinical research and development of drugs against leishman-
iasis in Africa has generally to overcome significant logistical
hurdles in terms of remote rural settings and lack of resources.
Through the establishment of the Leishmaniasis East Africa
Platform (LEAP), a network of researchers supported by DNDi
that implements and coordinates clinical trial activities in Sudan,
Ethiopia, Kenya, and Uganda, these hurdles were overcome. This
report emanates from the largest international study on VL and
the first phase III study on PM in Africa.
The PM dose regimen of 15 mg/kg/day was previously shown
to be highly efficacious with ,95% cure rates in the treatment of
VL in India [17]; however, in this study its efficacy varied
considerably by region. It was particularly low in eastern Sudan
(northern endemic zone), while being somewhat better in southern
Ethiopia and Kenya (southern endemic zone). However, overall
cure was only 63.8% and hence significantly and unacceptably
lower than that with SSG. This finding was pronounced and
robust as confirmed in both the complete-case and worst-case
analyses. Hence, even though the study was not designed to detect
differences among sites and despite some variable loss to follow-up
Table 3. Number of patients with adverse events.
SSG
n=135
PM
n=135
Deaths 3 (2.2%) 2 (1.4%)
Patients with SAE* 8 (5.9%) 5 (3.7%)
Treatment-emergent{ 7 (5.2%) 3 (2.2%)
During follow-up 1 (0.7%) 2 (1.4%)
Unrelated to study drug 3 (2.2%) 2 (1.4%)
Unlikely, possibly or probably related 5 (3.7%) 3 (2.2%)
Patients with at least one AE at any time 99 (73.3%) 77 (57.0%)
TEAEs{ 90 (66.7%) 65 (48.2%)
AEs during follow-up 35 (25.9%) 33 (24.4%)
TEAEs
Total number of TEAEs 169 112
Total patient-days at risk 8100 6885
TEAE rate 0.021 0.016
TEAE rate ratio (95% CI) comparing PM with SSG, adjusted for centre 0.78 (0.61 to 0.99, p=0.041)
Data are n (%) unless otherwise stated. AE=adverse event. SAE=serious adverse event. TEAE=treatment-emergent adverse event.
*No patient experienced more than one SAE.
{TEAEs defined as onset being between day 1 of treatment and 30 days after end of treatment inclusive. AEs occurring during follow-up had onset recorded as between
day 31 of trial and end of study.
doi:10.1371/journal.pntd.0000709.t003
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to be due to an individual site effect. A phase II trial testing
liposomal amphotericin B against primary VL showed differences
in site efficacy [19]. In this study, lower doses of amphotericin B
were needed to cure patients in India than to cure patients in
Kenya or Brazil.
Consequently, there have been three important outcomes
following these initial results. The first is that the evaluation of
PM at a dose of 15 mg/kg for 21 days was discontinued in the East
African countries. Second, because it is difficult to conclude what
the underlying causes of PM failure at a dose of 15 mg/kg/day
were, based on these data alone, a pharmacokinetic investigation
and regional drug sensitivity testing are currently underway to
assess whether patients or parasite factors may account for this
failure. The third outcome following a dose evaluation study was a
decision to continue evaluation of PM at a dose of 20 mg/kg for
21 days in comparison to both SSG and the combination (at the
doses previously used).
The reason to continue evaluation of PM is strengthened by
the fact that very few treatment options are available for the
management of VL in Africa [1]. Antimonials (either SSG or
meglumine antimoniate) remain the current first-line treatment
in all VL endemic countries. Miltefosine is neither yet registered
nor available in East Africa, and has only been evaluated in one
trial in Ethiopia [9]. Use of liposomal amphotericin B at its
currently recommended dose (20–30 mg/kg) remains limited by
cost, even with the recent cost reduction announced in 2007.
Furthermore, the most appropriate and practical dose for the
region has not been established; however, a clinical trial is
underway to assess this. PM is still the cheapest available VL
treatment, and its ease of use in resource-limited settings makes it
an attractive option [20]. As the drug seems efficacious and
relatively well-tolerated in India and in parts of East Africa, a
risk–benefit evaluation performed by LEAP favored the assess-
ment of an increased dose.
The intention remains that PM will be used in combination with
SSG, as this combination has already been used in the field setting
in south Sudan [16,21]. As shown with other diseases such as
malaria, combination therapy remains highly desirable as it may
maintain a high efficacy, reduce length of treatment, and protect
both drugs from development of resistance. Evaluation of PM
monotherapy at a dose of 20 mg/kg for 21 days and the
combination of SSG and PM at 15 mg/kg for 17 days has been
continued, and is expected to be completed in 2010. After results
are analyzed, a definitive decision can be made whether to
proceed with registration of PM and recommendation for use of
PM in combination with other anti-VL drugs in the VL endemic
countries in Africa. Although this study provides negative efficacy
results of PM monotherapy in some regions in East Africa, it has
strengthened regional clinical research capacity through LEAP
and has served as an essential cornerstone upon which further
prospective treatments will be evaluated.
Supporting Information
Protocol S1 Trial protocol details and amendments.
Found at: doi:10.1371/journal.pntd.0000709.s001 (6.45 MB PDF)
Checklist S1 CONSORT checklist.
Found at: doi:10.1371/journal.pntd.0000709.s002 (0.19 MB
DOC)
Table 4. Number of patients experiencing non-serious treatment-emergent adverse events (TEAEs).
SSG
n=135
PM
n=135
Gastrointestinal disorders 6 (4.4%) 6 (4.4%)
Abdominal pain 1 (0.7%) 2 (1.5%)
General disorders and administration site conditions 13 (9.6%) 19 (14.1%)
Injection site pain 12 (8.9%) 16 (11.9%)
Infections and infestations 14 (10.4%) 8 (5.9%)
Gastroenteritis 1 (0.7%) 2 (1.5%)
Pneumonia 2 (1.5%) 0 (0.0%)
Urinary tract infection 4 (3.0%) 1 (0.7%)
PKDL 5 (3.7%) 1 (0.7%)
Investigations 42 (31.1%) 24 (17.8%)
Hepatic enzymes increased 27 (20.0%) 14 (10.4%)
AP increased 7 (5.2%) 5 (3.7%)
Blood amylase increased 4 (3.0%) 0 (0.0%)
Blood creatinine increased 1 (0.7%) 3 (2.2%)
Nervous system disorders 2 (1.5%) 5 (3.7%)
Headache 1 (0.7%) 4 (3.0%)
Respiratory, thoracic and mediastinal disorders 6 (4.4%) 2 (1.5%)
Epistaxis 5 (3.7%) 2 (1.5%)
Skin and subcutaneous tissue disorders 6 (4.4%) 1 (0.7%)
Rash 2 (1.5%) 1 (0.7%)
Data are n (%). AP=alkaline phosphatase. PKDL=post-kala-azar dermal leishmaniasis. TEAEs listed above are related to the study drug with an incidence of at least 1%
in any group.
doi:10.1371/journal.pntd.0000709.t004
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